The company Biocross has developed two innovative blood tests, e4Risk® and e4Quant®, which identify and quantify the presence of the APOE4 gene, related to various metabolic and neurodegenerative diseases such as type 2 diabetes, cardiovascular diseases, and Alzheimer’s. A recent study by the Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona revealed that almost all individuals with a duplication of the APOE4 gene develop biomarkers associated with dementia. These tests represent a significant advancement in the early identification and management of these diseases, offering new hope for improving the health and quality of life of those affected.
Published in: “Enrique Castellón: “Un sencillo test puede identificar el riesgo o pronóstico de padecer Alzheimer en el futuro””, Educa-med.
